SentiBioLogo.jpg
Senti Bio to Participate in Upcoming Investor Conferences
03 sept. 2024 08h15 HE | Senti Biosciences, Inc.
Senti Bio will participate in two upcoming investor conferences in September.
cambrium-logo-black-1500px (5).png
Cambrium Secures €8 Million in Seed Funding to Commercialize New Class of Performance Molecules
31 oct. 2023 07h00 HE | Cambrium GmbH
Synthetic biology startup Cambrium announces €8 Million in Seed financing, led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital
Synlogic_Logo_Blue.png
Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
24 mai 2023 06h35 HE | Synlogic, Inc.
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at...
Synlogic_Logo_Blue.png
Synlogic to Present at the Jefferies Global Healthcare Conference
23 mai 2023 06h50 HE | Synlogic, Inc.
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B....
Synlogic_Logo_Blue.png
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
11 mai 2023 06h50 HE | Synlogic, Inc.
- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and...
Synlogic_Logo_Blue.png
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
09 mai 2023 06h50 HE | Synlogic, Inc.
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug...
Synlogic_Logo_Blue.png
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
29 mars 2023 06h40 HE | Synlogic, Inc.
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...
Synlogic_Logo_Blue.png
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
28 mars 2023 06h52 HE | Synlogic, Inc.
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines...
Synlogic_Logo_Blue.png
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
20 mars 2023 06h55 HE | Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic_Logo_Blue.png
Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference
08 mars 2023 07h00 HE | Synlogic, Inc.
CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B....